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3) Moreover, thrombin also activates blood platelets, 4, 5) and acts as a mitogen for various cell types. [6] [7] [8] Thus, thrombin has become a special target in the design and development of antithrombotic agents.
Various naturally occurring thrombin inhibitors have been found: hirudin (from the leech Hirudo medicinalis), 9, 10) cyclotheonamide A, B, and nazumamide A (from the marine sponge Theonella sp.), [11] [12] [13] [14] aeruginosin 298-A, aeruginosins 98-A and 98-B (from the blue-green alga Microcystis aeruginosa). [15] [16] [17] On the other hand, many compounds having benzamidine or arginine moiety as a partial structure have been synthesized and their inhibitory effects on thrombin examined. [18] [19] [20] [21] [22] [23] Argatroban (MD-805) proposed by Okamoto et al. 18) is one of most potent synthetic thrombin inhibitors (K i ϭ1.9ϫ10 Ϫ8 M) and is clinically used. Complexes of human or bovine a-thrombin with synthetic arginyl peptides have been analyzed by X-ray diffraction studies. [24] [25] [26] [27] [28] [29] [30] The X-ray data suggested that the thrombin active site consists of the specificity (S1) pocket, the hydrophobic proximal pocket (P-pocket), and the hydrophobic distal pocket (D-pocket). The guanidino nitrogen atoms of inhibitors form a salt bridge with Asp189 (numbering of the thrombin amino acid residues is based on the chymotrypsinogen nomenclature introduced by Bode et al.) 24, 28) in S1 pocket, and additional favorable interactions between the inhibitor and D-pocket or P-pocket enhance the inhibitory potency.
Cationic organic molecules such as benzamidine and phenylguanidine derivatives are potent inhibitors of trypsin and trypsin-like enzymes, [31] [32] [33] owing to the electrostatic interaction between the cationic group of inhibitor and an anionic residue at S1 site in the trypsin active site. It is known that salicylaldehyde spontaneously forms a very stable Schiff base metal chelate with an a-amino acid and metal ion. Therefore, we designed and synthesized amidino-or guanidino-containing Schiff base metal chelates (Chart 1) as trypsin-like enzyme inhibitors. [34] [35] [36] The manifold compounds in the series of A and B can be prepared by changing the combination of salicylaldehyde derivatives, various aamino acids, and metal ions, respectively.
Recently we proposed a new binding mode between trypsin active site and amidino-containing Schiff base metal chelate by X-ray diffraction study. 37) The cationic amidino group of chelates was shown to form a salt bridge with the carboxylate of Asp189 in the S1 pocket of trypsin as expected. In addition, it was evidenced that the metal ion and the phenolic oxygen of the Schiff base contribute additional interactions with His57 and Ser195 of trypsin.
In this report, the inhibitory effect of amidino-containing Schiff base copper(II) and iron(III) chelates for thrombin was analyzed and the structure-activity relationship between thrombin and inhibitor was also discussed based on the K i values.
Results and Discussion
Syntheses and Characterization of Schiff Base Metal Chelates Syntheses of the amidino-containing Schiff base copper(II) chelates (Chart 2; series 1) were achieved by mixing equimolar amounts of 4-formyl-3-hydroxybenzamidine hydrochloride, D-or L-amino acids, and copper(II) acetate, respectively. Syntheses of the copper(II) chelates (Chart 2; series 2) were also carried out in a similar manner using 3-formyl-4-hydroxybenzamidine hydrochloride. The corresponding iron(III) chelates (Chart 2; series 3 and 4) were prepared from 4-formyl-3-hydroxy-benzamidine hydrochloride or 3-formyl-4-hydroxybenzamidine hydrochloride, D-or Lamino acids, and iron(II) acetate, respectively. The formation of the Schiff base metal chelates was ascertained by the appearance of a marked absorption band at 360-380 nm for copper(II) chelates and at 430-480 nm for iron(III) chelates, [34] [35] [36] which can be attributed to a p→p* transition originating mainly from the azomethine chromophore.
Inhibition Constant (K i ) of Schiff Base Metal Chelates for Thrombin The inhibition constants (dissociation constants) of the Schiff base metal chelates with the thrombin were determined from a rate assay employing benzoyl-L-arginine p-nitroanilide (BAPA) as the substrate, and the K i values are listed in Table 1 . All the chelates behaved as competitive inhibitors for thrombin with K i values in the range of 10
Effect of Metal Ions
From the results of our previous studies, [34] [35] [36] the coordination geometry was shown to be an octahedral configuration for iron(III) chelates and a square planar configuration for copper(II) chelates, as is shown in 
Effect of the Position of the Amidino Group
In this study, we used two amidinosalicylaldehyde isomers, 4-formyl-3-hydroxybenzamidine and 3-formyl-4-hydroxybenzamidine. Difference of the position of the amidino group in the salicylaldehyde caused a dramatic change in the metal chelating structure, as shown in Chart 2. The amino acid side chain (R group) of series 1 is situated to the left of copper(II) ion, as shown in Chart 2. In contrast, for the compounds of series 2, the side chain (R group) of amino acid moiety is to the right of copper(II) ion. When the amidino group of chelate forms a salt bridge with the carboxylate of Asp189 at the thrombin active site, the localization of the R group for the two thrombin-chelate complexes was different. Therefore, the effect of position of the R group on inhibitory potency was apparent. This effect did, in fact, appear in the K i values of copper(II) and iron(III) chelates. The copper(II) and iron(III) chelates (series 1 and 3) derived from 4-formyl-3-hydroxybenzamidine and L-amino acids exhibit higher inhibitory potency compared to the chelates (series 2 and 4) derived from 3-formyl-4-hydroxybenzamidine and L-amino acids, as shown in Table 1 . Especially, the iron(III) chelates 3c-i have 100-1000 times higher inhibitory potency than chelates 4c-i. Similarly the iron(III) chelates (3cЈ-iЈ) derived from 4-formyl-3-hydroxybenzamidine and D-amino acids exhibit higher inhibitory potency than the chelates (4cЈ-iЈ) derived from 3-formyl-4-hydroxybenzamidine and D-amino acids. In the copper(II) chelates with D-amino acid, however, this tendency was not appreciable. The result suggests that the conformation of the thrombin active site is complementary for the chelates derived from 4-formyl-3-hydroxybenzamidine to a greater extent than those derived from 3-formyl-4-hydroxybenzamidine.
Effect of Amino Acid Inhibitory effect of the side chains and absolute configuration of the a-carbon was examined using both L-and D-enantiomers for 20 different a-amino acids. The Asp, Glu, Cys, Tyr, and Pro, however, did not form the Schiff base metal chelate. A control experiment was carried out with chelates with Gly (1a-4a), and their K i values were found to be less than 10 Ϫ5 M. Both copper(II) and iron(III) chelates (1c-h, 3c-h) derived from 4-formyl-3-hydroxybenzamidine and hydrophobic L-amino acids (Val, Leu, Ile, Phe, Trp, Met) exhibited a strong inhibitory effect on thrombin activity (K i ϭ10 Ϫ6 -10
In contrast, for the copper(II) and iron(III) chelates (1cЈ-hЈ 3cЈ-hЈ) derived from D-amino acid, no pronounced inhibitory potency was seen except for chelate 1gЈ from D-Trp, indicating that L-configuration has better interaction with the thrombin active site than D-configuration for compounds of series 1 and 3. No such phenomenon was observed, however, in the copper(II) and iron(III) chelates (series 2 and 4) . The low inhibitory potency (K i ϭ10 Ϫ4 M) of the iron(III) chelates (4c-i, 4cЈ-iЈ) for thrombin suggests that octahedrally coordinated iron(III) chelates derived from 3-formyl-4-hydroxybenzamidine and amino acid with bulky side chain could not be accommodated in the thrombin active site, i.e., unfavorable interactions with the active site residues occured.
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Structure-Activity Relationship The copper(II) chelate 1gЈ derived from 4-formyl-3-hydroxybenzamidine and D-Trp is the most potent inhibitor tested in this study. Its K i value is comparable to that (1.9ϫ10 Ϫ8 M) of Argatroban (MD-805) which is a clinically used compound.
Various X-ray diffraction studies [24] [25] [26] [27] [28] [29] [30] of thrombin-inhibitor clarified that the thrombin active site is mainly defined by the specificity S1 pocket, the hydrophobic Ppocket, and the hydrophobic D-pocket, as is shown in Figs. 1  and 2 . The S1 pocket consists of the carboxylate of Asp189 and backbone carbonyl in the bottom of the pocket. The P-pocket consisted of the Tyr60A and Trp60D 38) side chains, the imidazole ring of His57 of the catalytic triad, and the isobutyl group of Leu99, while the D-pocket consisted of the indole ring of Trp215 side chain, Ile174 side chain, and Glu97A-Leu99 side chains.
Nilsson et al. recently reported the X-ray crystal structure of thrombin-inhibitor complex, which contains benzamidine moiety. 30) Based on this structure, the schematic model for the most potent compound, 1gЈ, binding to the thrombin active site is shown in Fig. 1A . The strongly basic amidino group in 1gЈ forms a salt bridge with carboxylate of Asp189, and forms a hydrogen bond with carbonyl oxygen of Gly219 in the S1 pocket. Then the indole ring of 1gЈ results in close contact with the D-pocket. The location of the indole ring of 1gЈ must allow better fits into the D-pocket than that of 1g. On the other hand, the amino acid side chain of 2gЈ oriented away from the D-pocket, as shown in Fig. 1B . Therefore, no interaction could occur between this side chain and the D-pocket. This can explain why amino acid side chains have no remarkable effect on K i value in series 2 chelates.
In the iron(III) chelates, chelates 3c-i exhibited strong inhibitory potency, whereas those of 4c-i were decreased. The amino acid side chains in chelates 3c-i probably cause favorable interaction with the P-pocket, whereas that in chelates 4c-i cause unfavorable interactions with the Ppocket and D-pocket in the thrombin active site, as shown in Fig. 2 .
In this study we found a potent thrombin inhibitor 1gЈ. Further details of structural requirements for the thrombin1gЈ complex using the X-ray diffraction method will be described in a future paper.
Experimental
Materials and Instruments All chemicals for synthetic work were purchased from Sigma-Aldrich Co. (II) (1b, 2b) . 34) Bis(p-amidinosalicylidene-L-amino acidato)iron(III) (3b-o), bis(p-amidinosalicylidene-D-amino acidato)iron(III) (3bЈ-oЈ), bis(m-amidinosalicylidene-Lamino acidato)iron(III) (4b-o), and bis(m-amidinosalicylidene-D-amino acidato)iron(III) (4bЈ-oЈ) were synthesized according to the procedure reported for bis(p-amidinosalicyliden-L-alaninato)iron(III) or bis(m-amidinosalicylidene-L-alaninato)iron(III) (3b, 4b).
35)
Determination of Inhibitory Constant (K i ) of Inhibitors Enzyme activity was determined in 50 mM Tris-HCl buffer (pH 8.2) using BAPA as a substrate. Determination of K i values was carried out as follows: Concentrations of the inhibitor and thrombin used in the kinetic analysis were 10 Ϫ4 -10 Ϫ7 M and 10 Ϫ6 M, respectively. Hydrolytic rates in the presence of inhibitor were determined and the K i values were calculated according to the method of Dixon 39) using a linear regression program. 
